Overcoming chemoresistance to b-raf inhibitor in melanoma via targeted inhibition of phosphoenolpyruvate carboxykinase1 using 3-mercaptopropionic acid

Ming Ren*, Lu Wang*, Zi-Xu Gao†, Xin-Yi Deng, Kang-Jie Shen, Yan-Lin Li, Yi-Teng Ding, Chuan-Yuan Wei, and Jian-Ying Gu

Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

ABSTRACT
The resistance of melanoma to BRAF inhibitors remains a tough clinical challenge. In order to explore the underlying mechanism of drug resistance in melanoma, we established the resistant cell line to vemurafenib, and assessed the changes of drug-resistant cells on proliferation, apoptosis, oxidative stress and tumor stemness. Our results suggest that phosphoenolpyruvate carboxykinase1 (PCK1) is activated and inhibits the oxidative stress caused by vemurafenib in drug-resistant cells. Long term treatment of vemurafenib increases the expression of PCK1 which reduces the production of reactive oxygen species (ROS) by activating PI3K/Akt pathway. After the inhibition of PCK1 by 3-mercaptopropionic acid (3-MPA), the therapeutic sensitivity of vemurafenib is restored. In conclusion, this study disclosed that drug-resistant cells appeared to regulate their own proliferation, oxidative stress and tumor dryness by activating Akt/PCK1/ROS pathway, and shed new insights into acquiring drug resistance in melanoma.

Highlights
- PI3K/Akt pathway upregulated PCK1 in the resistant melanoma cells.
- PCK1 promoted proliferation and stemness, and reduced oxidative damage.
- 3-MPA sensitized vemurafenib by targeting PCK1, and suppressed the resistance via the Akt/PCK1/ROS axis.

Introduction
The incidence of melanoma, a malignant tumor of melanocytes that arises in the skin, has been increasing in recent years[1]. BRAF mutation is a prominent feature of melanoma, which activates the downstream kinase MEK/ERK within the MAPK pathway, promoting melanoma progression[2]. Inhibitors designed to target the...
BRAF mutation, such as vemurafenib, dabrafenib and combined therapy of dabrafenib and trametinib, have achieved pioneering results[3]. However inevitable acquired resistance is the major factor contributing to the treatment failure, innovative strategies are still urgently needed to improve the treatment of melanoma therapy.

Metabolic reprogramming is closely related to melanoma occurrence, development, metastasis, drug resistance, and recurrence [4,5]. PCK1, a cytoplasmic form of PEPCK, is a rate limiting enzyme, which decarboxylate in the second step of gluconeogenesis after the carboxylation of pyruvate, and then phosphorylates oxaloacic acid to form phosphoenolpyruvate (PEP) [6,7]. As a central molecule regulating glycolysis, the tricarboxylic acid cycle (TCA), and gluconeogenesis, PCK1 plays importantly biological effects [8]. Specifically, PCK1 is known to have a major role in generating abundantly NADPH to reduce the ROS through the Pentose Phosphate Pathway (PPP), which promotes the progression of colon and lung cancer [9]. The inhibition of PCK1 leads to metabolic imbalances, which hindering cell viability of transformed embryonal kidney and colon carcinoma tumor growth [10]. 3-MPA, a known inhibitor of gluconeogenesis, can inhibit PCK1 selectively, and shows a good performance in antitumor activity [11,12]. However, the mechanism of PCK1 in melanoma remains unknown and regulation of metabolic reprogramming may be an Achilles’ heel of chemoresistance.

In this study, we aimed to investigate the potential role of PCK1 in regulating acquired drug resistance in melanoma. Additionally, the effect of 3-MPA on sensitizing vemurafenib was validated by assays in vivo and in vitro.

Materials and methods

Establishment of resistant melanoma cells to vemurafenib

A2058 cells were inoculated in a culture flask, and a high dose of vemurafenib (PLX4032, Cat#HY-L032) (MedChemExpress, USA) was used for treatment. When most of the cells had died, the dead cells were washed away and the medium was changed to a drug-free medium. Post reaching confluence, the cells were digested and reinoculated into a new culture flask, and some cells were cryopreserved for RNA-seq. The cells were treated with high density vemurafenib until the cells reached 30% confluence. This process was repeated 3 times, and we obtained R0, R1, R2, and R3 cells, which were then used for RNA-seq analysis. Melanoma cells in the exponential growth phase were inoculated into culture bottles. After 48 h, the cells were transferred to a drug-free medium and expanded until the next mitotic phase. Then, the above steps were repeated using vemurafenib that was two times more concentrated. At the same time, cell death was observed every day, the fresh complete medium containing vemurafenib was replaced, and Cell Counting Kit 8 (CCK8) analysis was performed regularly until melanoma cells grew stably in the medium. This process lasted for six months, and transcriptome sequencing was performed once every two months; thus, 4 samples (R0, R1, R2, and R3) were obtained.

Knock down and overexpression

According to the instructions, Lipofectamine 3000 (American life technologies) was used for cell transfection. After 72 hours, western blot was used to detect the transfection efficiency. siPCK1, pLVX-shRNA-eGFP-PGK-Puro and CMV-H_PCK1-eGFP-3flag-PGK-Puro lentiviral vectors were purchased from Genomeditech (Shanghai, China). In short, A2058 cell lines were planted into 6-well plates and transfected at 5 × 10^5 cells per well (20 nM siRNA or shRNA). After 24 hours of transfection, the cells were replaced with fresh complete culture medium, and the cells were collected for follow-up experiments (lentivirus group needed to be screened by 2 ug/ml puromycin). The target sequences were as follows: siPCK1 GCACATCCCAACTCTCGATTT.

CCK8 cell proliferation assay

Cells were seeded in to a 96-well plate at a density of 4000 cell/well and cultured in a humidified cell culture incubator. After 24 hours, therapeutic drugs were added to the plate and continue to culture for 72 hours. 10 μL CCK8 reaction solution (Beyotime, China) was added to the cell culture at indicated
time point and incubated for 3 h in cell culture incubator. The light absorption value (Optical Density value, OD) in each condition was measured at 450 nm wavelength on a Synergy H1 microplate reader (Winooski, Vermont, USA). The cell viability was calculated using the following formula: (OD of dosing well – OD of culture medium)/(OD of control well – OD of culture medium) × 100%.

**Calculation of resistance index (RI)**

The 50% inhibitory concentration (IC50) calculator ([https://www.aatbio.com/tools/ic50-calculator](https://www.aatbio.com/tools/ic50-calculator)) was used to prepare the survival rate and drug concentration curves, and the best fitting IC50 was calculated. The statistical figure of the IC50 value was drawn by GraphPad prism 6 software. The following formula was used: RI = IC50 of resistant cells/IC50 of parental cells.

**Cell migration and trans-well invasion assay**

Ability of migration and invasion were examined by wound healing assay and trans-well assay respectively, and they were conducted as reported previously [13].

**Western-blotting analysis and antibodies**

The total protein was obtained from all cells using RIPA buffer (Sigma, USA), and then the protein was quantified by BCA Kit (beyotime, China). Subsequently, 10 μg of protein was separated using 10% sodium dodecyl sulfate polyacrylamide gel, and then electrically transferred to polyvinylidene fluoride membrane, blocked with 5% skimmed milk for 2 hours, and incubated with primary antibody at 4°C for 8 hours, next, the membrane was incubated with secondary antibody at 37°C for 1 hour. Finally, the protein bands were observed by ECL system (Thermo, USA). All the antibodies used are listed in supplementary table 1.

**Cell apoptosis analysis**

Flow cytometry was performed as reported previously [14] and the Annexin V Apoptosis Detection Kit APC was obtained from eBioscience. The specific gating strategies applies to supplementary material.

**ROS detection in cells and tissues**

CellROX Regent orange solution was used to culture or cover the tissue and avoid light during the whole process. After incubation for 30 min at 37°C, we used a High Content Imaging System to observe the production of ROS in the cells. The dye solution was removed from the tissues and they were fixed. Then, photos were taken under a microscope, and the tissues were stored.

**Immunohistochemistry**

The tumor tissues were dehydrated and fixed in a 10% formalin buffer solution for 24 h. The frozen sections were embedded in OCT, frozen, and continuously sectioned to 15 μm sections at 20°C. Immunohistochemistry was performed as previously described. The primary antibodies used are listed in Table S1.

**Animal models**

Parental A2058 cells or drug-resistant melanoma A2058R cells (1 × 10⁶) in 200 μl of PBS were subcutaneously transplanted into SPF BALB/c nude mice (purchased from Zhongshan Hospital Laboratory). After 7–10 days of transplantation, the palpable tumor size (40–100 mm) was reached, and mice with a similar tumor size were randomly assigned to different four treatment groups. The parallel group design was adopted, and the mice were treated with 30 mg/kg vemurafenib, and/or 3-mercaptopicolinic acid (SKF-34288 hydrochloride, Cat#320,386-54-7) (MedChemExpress, USA) [15], and equal DMSO, once a day for 21 days. All animal protocols were approved by the animal protection and the use committee of Zhongshan Hospital, Fudan University.

**Calculation of the combination index**

CompuSyn is available for download from [http://www.combosyn.com](http://www.combosyn.com). According to the Chou-Talalay mathematical model of drug interaction,
the combination index (CI) of cells receiving combination therapy was calculated. Chou-Talalay CI theorem provides a quantitative definition of the additive effect (CI = 1), synergistic effect (CI < 1), and antagonistic effect (CI > 1) of drug combination [16].

**Statistical analysis**

Each experiment was repeated three times. The results were shown by the mean ± standard deviation. SPSS software 19.0 was used for the statistical analyses, including Student’s t-test (two-tailed), Pearson’s correlation analysis, and the Log-Rank test. The significance threshold was set at 0.05 for each test.

**Results**

PCK1 was a highly expressed protein in drug-resistant melanoma cells. In this study, we investigated the potential role of PCK1 in modulating the resistant phenotype of malignant melanoma. Our study revealed that overexpression of PCK1 promoted cell proliferation, invasion, and tumor stemness, and reduced the oxidative damage induced by vemurafenib. After using 3-MPA, a specific inhibitor to PCK1, acquired drug resistance to vemurafenib could be relieved. The role of PCK1 and 3-MPA were validated in the mouse xenograft model.

**Establishment and phenotype of the drug resistance model**

To investigate the molecular mechanisms underlying resistance of b-raf inhibitor, we exposed the melanoma cell line A2058 harboring the BRAF V600E mutation to high concentrations of vemurafenib. After 6 months, we obtained the resistant cell line A2058R. We found that the cells became slender under the action of vemurafenib at a high concentration (Figure 1a, 1b). Results of the CCK8 experiment confirmed that the IC₅₀ of drug-resistant A2058R cells was higher than that of primary A2058 cells, (A2058 IC₅₀ = 0.71, A2058R IC₅₀ = 21.95, RI = 30.9) (Figure 1c, 1d). Scratch and trans-well assays confirmed that A2058R cells have greater invasion and migration abilities than A2058 cells (Figure 1e–1i). Meanwhile, WB assays showed that the levels of CD271, SOX10, TWIST, and SLUG were elevated in A2058R cells, indicating that they possess higher stemness and abilities of Epithelial-to-Mesenchymal Transition (EMT).

**PCK1 protein and AKT/PI3K signaling were key factors in the transcriptome sequencing results**

After normalizing the transcriptome sequencing results (Figure 2a), we found that there were differences in the gene expression profiles among the four samples (Figure 2b), which were further corroborated by PCA results (Figure 2c). Differential expression analysis was performed, and we focused on PCK1, a gene whose expression level was high and constant in R1, R2, and R3, and we considered it as the key target gene for conferring of drug resistance (Figure 2d). In KEGG enrichment analysis (Figure 2e), we observed that the PI3K/AKT signaling pathway molecules were continuously highly expressed in the three drug-resistant samples. Combining with the related literatures „PCK1 and PI3K/Akt signaling pathways were involved in the process of acquired drug resistance induced by b-raf inhibitor in melanoma cells. Furthermore, western blot analysis confirmed the reasoning. In addition, when we inhibited the PI3K/Akt pathway, the expression of PCK1 decreased, suggesting that PCK1 is a crucial downstream molecule drug resistance (figure 2f).

**PCK1 activity determined melanoma cell resistance to vemurafenib**

Next, we constructed low expression and overexpression PCK1 cell lines using siRNA and overexpression viruses, respectively. Western blot results indicated that the transfection was successful (Figure 3a). After PCK1 knockdown, cell viability significantly reduced, thus, the IC50 of siPCK1 and the resistance index (RI) both decreased (RI = 4.46), P < 0.005 (Figure 3b, 3c).

However, the cell viability and resistance index (RI) were higher (RI = 9.27), P < 0.005, in the cell line overexpressing PCK1 (Figure 3b, 3d). Therefore, the results indicated that PCK1 was a crucial molecule that could enhance the tolerance of melanoma cells to vemurafenib.
PCK1 promoted the proliferation, migration, and stemness of melanoma cells with V600E mutation

Based on the hypothesis that the development of drug resistance might be caused by related genes that induce cancer stemness, EMT, and apoptosis inhibition, we first designed scratch and invasion experiments and found that the PCK1 gene status was related to the proliferation and invasion of melanoma cells, while the activation of PCK1 could promote drug resistance in melanoma and increase the severity of the disease (Figure 4a, 4b). Next, flow cytometry was conducted, and the results showed that the
knockdown and overexpression of PCK1 did not have a direct effect on apoptosis, although statistical differences were noted. This suggested that PCK1 might indirectly induce BRAFi resistance through PPP (Figure 4c–4g). In addition, the results of the tumor spheroidization test on a low adhesion plate showed that the spheroidization ability of A2058R cells was significantly higher than that of A2058 cells (Figure 4h), that of the SiPCK1 group was decreased, and that of
the OE group was restored after the overexpression of PCK1. Combined with the western blot results, these results suggested that CD271 and SOX10, which have been recognized as indicators of melanoma stemness, were highly expressed in A2058R and OE cells (Figure 4i), indicating that PCK1 could modify cancer stemness in the development of drug resistance. Meanwhile, in this experiment, PCK1 could not alter the EMT of melanoma for achievement of drug resistance (Figure 4j). These lines of evidence illustrated that the activation of PCK1 potentiated melanoma proliferation, migration, and tumor stemness, all the phenotypes associated with drug resistance. The results revealed that PCK1 did not contribute to drug resistance directly by inhibiting apoptosis but, most likely, contributed indirectly to acquired drug resistance.

**Synergistic effect of PCK1 inhibitor 3-mercaptopicolinic acid combined with vemurafenib on drug-resistant cells**

The CCK8 assay was used to detect the activity of A2058R cells under different drug treatment regimens. The IC50 of A2058R cells treated with 3-mercaptopicolinic acid or vemurafenib alone did not change significantly (Figure 5a, 5c). However, the IC50 of 3-mercaptopicolinic acid combined with vemurafenib was significantly lower than that of vemurafenib alone, which indicated that 3-mercaptopicolinic acid increased the resistance inhibition of vemurafenib (Figure 5b, 5c). We used the Chou-Talalay method to compare the efficacy of each treatment group. IC50(3-MPA + vemu) = 6.37, IC50(vemu) = 14.47, IC50 (3-MPA) = 27.47, and the combination index (CI) = 0.3362 < 1, which showed a synergistic

---

**Figure 3.** Effect of PCK1 on the chemoresistance in melanoma cells.

A. Western blot: the melanoma cell lines with low expression and overexpression of PCK1 were constructed successfully. B. IC50 figure: Knockdown of PCK1 shows low cell viability under vemurafenib, and overexpression shows high (* p < 0.05). C. Cell viability curve: the blue refers to the control, and the red refers to the knockdown (siPCK1). D. Cell viability curve: the blue represents the empty virus (EV), and the red represents the overexpression (PCK1).
Figure 4. Functions of PCK1 in melanoma proliferation, migration, apoptosis, stemness, and EMT.

A. Scratch assay. B. Results of the scratch assay: the proliferation area of siPCK1 cells is smaller than the control, and the proliferation area of PCK1 group is higher than that of EV. C. Flow cytometry of apoptosis: the Q2 + Q3 is the proportion of apoptotic cells. The percentage of apoptotic cells is 0.9% in the control group. D. Flow cytometry of apoptosis: the percentage of apoptotic cells is 0.53% in the EV group. E. Flow cytometry plot: there is no significant difference in the distribution of apoptotic cells. F. Flow cytometry plot: the percentage of apoptotic cells in the siPCK1 group was 1.05%. G. Flow cytometry plot: the percentage of overexpression of the PCK1 group was 1.11%. H. Results of the sphere formation assay: counting the number of cell spheres with a diameter larger than 50 µm under a field of view. I. Western blot: proteins related to stemness. J. Western blot: proteins related to EMT.
effect on pharmacology (Figure 5d, 5e). Moreover, only when the reaction part of the system reaches an 0.8 < Fa < 0.9, the synergistic effect will be reversed to the antagonistic effect, so the synergistic effect is stable (figure 5f).

**Inhibition of PCK1 by 3-mercaptopicolinic acid led to ROS accumulation and oxidative damage in drug-resistant cells**

PCK1 was a key enzyme in the PPP process which controls the levels of intracellular ROS. Therefore, we speculated that the downstream mechanism of PCK1 might be related to the regulation of ROS levels. We used the High Content Live Cell Imaging System to observe the level of ROS. As shown in Figure 6a, we found that the ROS in primary A2058 cells was significantly higher than that in A2058R (Figure 6b). When A2058R cells were exposed to vemurafenib, the level of ROS was still lower than that in A2058 cells. In addition, the levels of ROS in primary A2058 cells and drug-resistant A2058R cells increased after adding 3-MPA. When A2058 and A2058R cells were treated with 3-MPA+vemurafenib, the ROS increased significantly, which suggested that the level of ROS in drug-resistant cells was determined by the activity of PCK1.

We generated a subcutaneous xenograft model from nude mice, forming cryosections, and analyzed by ROS probe (Figure 6c). Combined with the tumor volume (Figure 7d, 7e), we found that there were higher ROS in the A2058+ vemurafenib group than in the A2058+ DMSO group, whereas the number of tumor cells was reduced relative to the A2058+ DMSO group, indicating
that vemurafenib inhibited progression by generating strong oxidative damage. Compared with the A2058R+vemurafenib group, the A2058+vemurafenib group exhibited higher ROS but less cells, indicating that the drug-resistant cells hedge the killing effect of vemurafenib via regulation of ROS. Compared with the A2058R+vemurafenib group, the A2058R+3-MPA+vemurafenib group showed a significant increase of ROS but a decrease in the number of tumor cells, which demonstrated that the inhibition of PCK1 sensitized melanoma to vemurafenib. When we added 3-MPA (20 umol/L) to A2058 and A2058R cells, the WB results showed that the expression of KEAP1 was increased, which indicated that PCK1 inhibited the expression of KEAP1 (Figure 6d). 3-MPA blocked PCK1, thereby enabling ROS accumulation and suppressing chemoresistance in melanoma cells.

Figure 6. PCK1 led to drug resistance by reducing ROS accumulation.
A. ROS imaging: The red area is the result of ROS probe combined with intracytoplasmic ROS, and the white area represents the nuclear components. B. Result of ROS imaging. C. Detection of ROS in frozen tissue: the sliced tissues were derived from the subcutaneous tumorigenesis nude mice model. P represented the subcutaneous tumor formed after inoculation with melanoma A2058 cells, R represented the subcutaneous tumor formed after inoculation with drug-resistant A2058R cells, red represented the ROS, blue represented the nuclei (DAPI). The redder the color, the higher the content of ROS in the tissue. D. Western blot: KEAP1 expression increased after the addition of 3-mercaptopicolinic acid in A2058 and A2058R cells.
3-mercaptopicolinic acid improved the inhibitory effect of BRAFi in vivo

Next, we evaluated the effect of combination therapy in melanoma using a subcutaneous xenograft mouse model (Figure 7a, 7b). According to the weight and volume data (Figure 7c, 7d), we found that the combination of vemurafenib and 3-mercaptopicolinic acid in the drug-resistant group could reverse the drug-resistant situation and significantly reduce the wet and volume of the tumor tissue.
Compared with A2058 primary melanoma cells, the inhibition ability of the combination group was even more prominent, which suggested that the combination of BRAFi and PCK1 could achieve an excellent inhibition effect in resistant cells with PCK1 mutation. Combined with the immunohistochemical results, mentioned above, we further confirmed the main effect of 3-MPA was to increase ROS.

The immunohistochemistry results showed that in the subcutaneous tumor tissues of nude mice inoculated with primary A2058 cells, the expression of PCK1 in the vemurafenib group was up-regulated compared with the DMSO group, while KEAP1 was inhibited (Figure 6d). In the tissues of A2058R cells, the expression of PCK1 was limited, but the expression of KEAP1 was up-regulated. Therefore, both the in vitro and in vivo experiments confirmed that vemurafenib could induce high expression of PCK1, and then inhibit the synthesis of KEAP1. However, when 3-MPA was used to inhibit PCK1, KEAP1 was activated leading to ROS accumulated, which caused oxidative attack to resistant melanoma cells.

**Discussion**

Acquired resistance is the main clinical obstacle to improving the prognosis of melanoma patients, and the known mechanisms involve various components [17,18]. The most common pathological mechanisms are the reactivation of the BRAF/MEK pathway or other proliferation promoting signal transduction pathways, the increasing copy number in the BRAF V600E protein, RAS mutations, and the activation of a-raf and c-raf, which promote the formation of a dimer that b-raf inhibitor cannot work[19,20]. Moreover, the mutation of MEK1/MEK2 and the high expression of COT lead to the activation of the MAPK/ERK pathway downstream of b-raf[21]. Overexpressed RTKs and the compensatory up-regulation of the Akt/PI3K/mTOR pathway contribute to the drug resistance [22,23]. Our study also demonstrated that the adaptive hyperactivation of AKT in response to BRAFi compensated for b-raf inactivation. Therefore, we concluded that the AKT/PI3K/mTOR pathway was an extremely important signaling axis, promoting cell proliferation, migration, and stemness, which contributed to BRAFi resistance in V600E mutated melanoma.

Although there are many downstream effectors of PI3K and Akt that can change the function of melanoma cells, PCK1 synthesis and activation are important processes mediated after AKT phosphorylation. The Akt/PI3K/mTOR pathway is mainly related to the mechanism of metabolic reprogramming[24], including the activation of mTOR complex 1 (mTORC1), glycogen synthase kinase 3 (GSK3), and forkhead box O (FoxO) transcription factor family members [25,26]. In our study, the activity of the Akt/PI3K/mTOR pathway and the PCK1 levels always paralleled each other in vitro, probably because the activation of mTORC1-induced cytosolic SREBP to promote PCK1 synthesis[27]. Additionally, FoxO1 deacetylation synergized PGC-1α action to promote PCK1 transcription. It has recently been reported that activated Akt can directly phosphorylate PCK1 at Ser-90[28]. Ultimately, the biological processes mediated by PCK1 under the agonism of AKT are critical steps for drug resistance in melanoma.

A redox homeostasis imbalance elevates ROS levels and is pivotal in driving the processes of carcinogenesis, metastasis, and drug resistance in cutaneous melanoma [29,30]. Lim pointed out that was the process of redox metabolism rewiring in melanoma cells[31]. During the course of long-term treatment with BRAFi, the upregulated MITF-PGC1α axis and the long non-coding RNA (lncRNA) SAMMSON-p32 led to an inevitable accumulation of ROS[32]. High levels of ROS should have induced apoptosis, but genetic changes led to survive at high levels of ROS by increasing the NADPH level through the PPP or by activating the KEAP1 /Nrf2 antioxidant signaling pathway [33,34]. One of the crucial switches driving redox remodeling was PCK1, which was a key enzyme involved in the PPP process[35], playing a role in the antioxidant function of tumors[36]. This required the presence of PCK1 to synthesize abundant reductive NADPH via the PPP, and its inhibition impeded the growth of melanoma[37]. Moreover, PCK1 repressed KEAP1 and the Nrf2 restriction was removed, further activating the antioxidant repair ability of
Thus, a large amount of reductive NADPH was produced, which counteracted the cell damage induced by high levels of ROS, and promoted cells to achieving redox equilibrium to survive.

Studies on the role of redox fragility in melanoma progression have been reported, and BRAFi-resistant melanoma cells with elevated ROS levels are more sensitive to the oxidants [38]. This is highly consistent with our results, which shows that 3-mercaptopicolinic acid sensitizes the biological effect of vemurafenib and restores the sensitivity of tumors. When 3-mercaptopicolinic acid was used, drug-resistant cells lost the ability of supplementing the reduction equivalent, the redox level was unbalanced again, and the cells experienced oxidative damage. The specific mechanism underlying this effect might be that 3-mercaptopicolinic acid blocked the PPP to synthesize NADPH and nucleic acids, which resulted in inhibition of proliferation and accumulation of intracellular ROS. Interestingly, the increase in ROS level should play a protective role through the KEAP1/Nrf2 axis. However, when 3-mercaptopicolinic acid was used, the expression of KEAP1, a repressor of Nrf2, increased [39]. As the KEAP1/Nrf2 axis had cellular protective effects on the antioxidant and detoxification activities [40], inhibiting Nrf2 undoubtedly aggravated the oxidative burden of tumor cells. These results suggested that
3-mercaptopicolinic acid not only down-regulates the PPP, but also indirectly up-regulates KEAP1, leading to the imbalance of antioxidant system in drug-resistant cells. As a result, the combination of 3-mercaptopicolinic acid and vemurafenib shows an outstanding therapeutic effect.

One limitation in our study is that only the melanoma A2058 cell line was used for modeling. Moreover, the drug resistance was a relatively long-term change, and the observation time used in our in vitro and in vivo experiments was relatively short. Therefore, the role of PCK1 in the drug resistance process of other tumor cells needed to be further revealed, and the observation cycle also needs to be optimized to explore the specific functions of PCK1 from a long-term and objective perspective.

**Conclusion**

We found that the Akt/PI3K/mTOR signaling pathway was activated in resistant melanoma cells, and then PCK1 was upregulated in also promoted cell proliferation, migration, and tumor stemness. And then, PCK1 decreased the expression of KEAP1 and the leave of ROS (Figure 8). Based on the strategy of precision treatment, we used an antihyperglycemic agent 3-MPA combined with vemurafenib and found it enhanced the sensitivity of drugs obviously. Finally, we clarified the mechanism of resistance to vemurafenib and provided new options for clinically targeted combination therapy in patients with advanced melanoma.

**Acknowledgements**

The project was supported by the National Natural Science Foundation of China. The authors thank the Zhongshan hospital of Fudan University for technical assistance and support from professor Jian-Ying Gu.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by the [National Natural Science Foundation of China] under Grant [number 81972559].

**Data availability statement**

The data used to support the findings of this study are available from the corresponding author on reasonable request. Click here

**Author contributions**

(A) R.,C.W. and J.G. came up with the hypothesis and designed the experiments. M.R. and X. D. performed cell experiments. Z.G. and Y. L. performed the animal experiments. K.S., Y. D. and Y.L. interpreted the data. M.R. and L. W. wrote the manuscript. J.G. and C. W. supervised the overall research, secured funding, and interpreted results. All authors read and approved the final manuscript.

**Ethics statement**

Animal researches were executed in compliance with the Institutional Animal Use and Care Committee of Zhongshan hospital. Details are in supplementary materials.

**References**

[1] Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27;417 (6892):949–954.
[2] Ottaviano M, Giunta EF, Tortora M, et al. On behalf of scito youth. BRAF gene and melanoma: back to the future. Int J Mol Sci. 2021 Mar 27;22(7):3474.
[3] Wang W, Smith JL, Carlino MS, et al. Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Clin Transl Radiat Oncol. 2021 Aug 14;30:95–99.
[4] Wan M, Zhuang B, Dai X, et al. A new metabolic signature contributes to disease progression and predicts worse survival in melanoma. Bioengineered. 2020 Dec;11(1):1099–1111.
[5] Han A, Schug ZT, Aplin AE. Metabolic alterations and therapeutic opportunities in rare forms of melanoma. Trends Cancer. 2021 Aug;7(8):671–681.
[6] Xu D, Wang Z, Xia Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature. 2020 Apr;580(7804):530–535.

[7] Li Y, Luo S, Ma R, et al. Upregulation of cytosolic phosphoenolpyruvate carboxykinase is a critical metabolic event in melanoma cells that repopulate tumors. Cancer Res. 2015 Apr 1;75(7):1191–1196.

[8] Wang Z, Dong C. Gluconeogenesis in cancer: function and regulation of PEPCK, FBPase, and G6Pase. Trends Cancer. 2019 Jan;5(1):30–45.

[9] Ma R, Ji T, Zhang H, et al. A PCK1-directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells. Nat Cell Biol. 2018 Jan;20(1):21–27.

[10] Aragó M, Moreno-Felici J, Abás S, et al. Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M. Biomed Pharmacother. 2020 Jan;121:109601.

[11] DiTullio NW, Berkoff CE, Blank B, et al. 3-mercapto-picolinic acid, an inhibitor of gluconeogenesis. Biochem J. 1974 Mar;138(3):387–394.

[12] Aragó M, Moreno-Felici J, Abás S, et al. Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M. Biomed Pharmacother. 2020 Jan;121:109601.

[13] Zou W, Liu B, Wang Y, et al. Metformin attenuates high glucose-induced injury in islet microvascular endothelial cells. Bioengineered. 2022 Feb;13(2):4385–4396.

[14] Barteneva NS, Fasler-Kan E, Vorobjev IA. Imaging flow cytometry: coping with heterogeneity in biological systems. J Histochem Cytochem. 2012 Oct;60(10):723–733.

[15] Yoshihara HAI, Comment A, Schwitter J. Assessment of aspartate and bicarbonate produced from hyperpolarized [1-13C] pyruvate as markers of renal gluconeogenesis. Front Physiol. 2021 Dec 10;12:792769.

[16] Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010 Jan 15;70(2):440–446.

[17] Gide TN, Wilmott JS, Scolyer RA, et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018 Mar 15;24(6):1260–1270.

[18] Chen G, Davies MA. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Hematol Oncol Clin North Am. 2014 Jun;28(3):523–536.

[19] Patel H, Yacoub N, Mishra R, et al. Current advances in the treatment of BRAF-mutant melanoma. Cancers (Basel). 2020 Feb 19;12(2):482.

[20] Sharma V, Young L, Cavadas M, et al. Reproducibility project: cancer biology. Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Elife. 2016 Mar 21;5:e11414.

[21] Chan XY, Singh A, Osman N, et al. Role played by signalling pathways in overcoming BRAF inhibitor resistance in melanoma. Int J Mol Sci. 2017 Jul 14;18(7):1527.

[22] Caporalì S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016 Sep;49(3):1164–1174.

[23] Manning BD, Toker A. AKT/PI3K signaling: navigating the network. Cell. 2017 Apr 20;169(3):381–405.

[24] Webb AE, Brunet A. FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci. 2014 Apr;39(4):159–169.

[25] Yi J, Zhu J, Wu J, et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31189–31197.

[26] Xu D, Wang Z, Xia Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature. 2020 Apr;580(7804):530–535.

[27] de Jager TL, Cockrell AE, Du Plessis SS. Ultraviolet light induced generation of ROS. Adv Exp Med Biol. 2017;996:15–23.

[28] Tsoi J, Robert L, Paraíso K, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018 May 14;33(5):890–904.e5.

[29] Cannavò SP, Tonacci A, Bertino L, et al. The role of oxidative stress in the biology of melanoma: a systematic review. Pathol Res Pract. 2019 Jan;215(1):21–28.

[30] Corazza-Rozas P, Guerreschi P, Jendoubi M, et al. Mitochondrial oxidative stress is the Achilles’ heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget. 2013 Nov;4(11):1986–1998.

[31] Hayes JD, Dinkova-Kostava AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020 Aug 10;38(2):167–197.

[32] Haq R, Fisher DE, Widlund HR. Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res. 2014 May 1;20(9):2257–2263. Epub 2014 Mar 7. PMID: 24610826; PMCID: PMC4008642.

[33] Vieira P, Cameron J, Rahikkala E, et al. Novel homozgyous PCK1 mutation causing cytosolic phosphoenolpyruvate carboxykinase deficiency presenting as childhood hypoglycemia, an abnormal pattern of urine metabolites and liver dysfunction. Mol Genet Metab. 2017 Apr;120(4):337–341.

[34] Tuo L, Xiang J, Pan X, et al. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis. J Exp Clin Cancer Res. 2019 Feb 4;38(1):50.

[35] Tang K, Zhu L, Chen J, et al. Hypoxia promotes breast cancer cell growth by activating a glycoligen metabolic program. Cancer Res. 2021 Oct 1;81(19):4949–4963.
[36] Montal ED, Dewi R, Bhalla K, et al. PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth. Mol Cell. 2015 Nov 19;60(4):571–583.

[37] Tsoi J, Robert L, Paraizo K, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018 May 14;33(5):890–904.e5.

[38] Obrador E, Liu-Smith F, Dellinger RW, et al. Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. Biol Chem. 2019 Apr 24;400(5):589–612.

[39] Itoh K, Wakabayashi N, Katoh Y, et al. Kelch-like ECH-associated protein 1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999 Jan 1;13(1):76–86.

[40] Cuadrado A, Rojo AI, Wells G, et al. Therapeutic targeting of the NRF2 and KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr; 18(4):295–317.